Lung Cancer

Roche recently announced the FDA accepted their supplemental biologics license application and granted priority review to atezolizumab for the treatment of non-small cell lung cancer.

The FDA granted a priority review to the new drug application for lurbinectedin as a treatment for patients with small cell lung cancer.

Medical oncologsts discuss the case of a 70-year old woman with synchronous multiple primary lung cancer.

Among participants who were current or former smokers, the NELSON trial found that volume CT screening enabled a significant reduction of harms without jeopardizing favorable outcomes.

The FDA granted a priority review to capmatinib, a MET inhibitor being analyzed for the first-line treatment of previously treated patients with METex14-mutated advanced NSCLC.

In observing individuals aged 65 and older suffering from a recent nonmetastatic cancer, researchers indicated that there is a need to change attitudes toward aging and older people.

The agency granted full approval to pemetrexed for injection (Pemfexy), a liquid injection and branded alternative to Alimta, for nonsquamous NSCLC.

Researchers indicated that a lack of understanding of the mechanism and efficacy of PD-1/PD-L1 inhibitors is the major barrier for prescription of these inhibitors in Chinese tumor treatment-related departments.

Inconsistencies observed by researchers on these websites indicated that efforts are needed to improve website content and readability.

Delivering the PDA to clients of tobacco quit lines, researchers highlighted the importance of broader dissemination and greater effect of the intervention.

Researchers found that through inheritable changes of gene expression, chronic exposure to IL-1β can promote lung cancer metastasis, without altering DNA sequence.

According to researchers, when individuals quit smoking it not only stops further damage from accruing, but it also may lead to the reawakening of cells that were not damaged by tobacco carcinogens.

Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer.

A recent study indicated that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.

Although concurrent chemotherapy and radiation is considered standard care, treatment of locally advanced NSCLC continues to be challenging, leading researchers to search for patients who may benefit from the addition of cyclooxygenase 2 inhibitors.

The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.

A 40-year-old woman presented with a productive cough and shortness of breath that limited her regular activities. Her past medical history was relevant for hypertension since 2016; it is well controlled and treated with enalapril 5 mg twice daily. She also revealed a past wood smoke exposure of 2 hours per day for 10 years during her childhood.

Data from the ongoing phase I/II ARROW clinical trial will be used to support a new drug application submission for pralsetinib to the FDA for the treatment of patients with RET fusion-positive non-small cell lung cancer.

The approach was created by the University of Michigan Rogel Cancer Center to limit variability and investigator bias.

These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.

In our lung cancer quiz, you'll get a chance to test your knowledge of the mortality risk among patients with lung cancer, and learn more about screening criteria to try reduce these rates.

Single dose radiotherapy may be as effective as 5 doses for patients with spinal canal compression from metastatic cancer.

To improve quality of life for patients with depression, researchers indicated it is crucial to provide referral and follow-up mental health care for patients with non-small cell lung cancer.

Integrated analyses showed entrectinib to be both effective and well tolerated in patients with rare ROS1 and NTRK gene fusions.

Patients with metastatic non-small cell lung cancer who harbor HER2-mutations may develop brain metastases more frequently during treatment.